AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Serina Therapeutics reports Q3 FY25 financial results, FDA approves 505(b)(2) NDA for SER-252.
ByAinvest
Thursday, Nov 13, 2025 6:12 am ET1min read
• Serina Therapeutics reports Q3 2025 financial results • FDA aligns with plan to advance SER-252 under 505(b)(2) NDA pathway • FDA recognizes Phase 1b trial as registrational • POZ platform streamlines development timelines and unlocks value across pipeline • SER-252 for advanced Parkinson's disease enabled by POZ Platform™ drug optimization technology • SER-252's accelerated path to potential approval underscores regulatory and development strategy.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet